Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Leuk Lymphoma Retrieve available abstracts of 246 articles: HTML format

Single Articles

October 2025
1. MCCORMICK B, Findley A, Diebold K, Bourne G, et al
   Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia.
   Leuk Lymphoma. 2025 Oct 10:1-11. doi: 10.1080/10428194.2025.2564766.
   PubMed     Abstract available
   
   
   
2. PARK H, Lee JH, Lee JH, Park HS, et al
   Optimal conditioning intensity: favorable outcome of a 3-day busulfan based regimen in younger acute myeloid leukemia patients.
   Leuk Lymphoma. 2025 Oct 10:1-14. doi: 10.1080/10428194.2025.2560086.
   PubMed     Abstract available
   
   
   
3. TADMOR T, Demeter J, Fagarasanu A, Kreitman RJ, et al
   Expert consensus opinion on the management of hairy cell leukemia in elderly patients.
   Leuk Lymphoma. 2025 Oct 10:1-7. doi: 10.1080/10428194.2025.2562961.
   PubMed     Abstract available
   
   
   
4. WATRIN T, Seifert M, Dietrich S
   The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN).
   Leuk Lymphoma. 2025 Oct 6:1-10. doi: 10.1080/10428194.2025.2562951.
   PubMed     Abstract available
   
   
   
5. HUANG YH, Liu FT, Wan CL, Wang ZJ, et al
   Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis.
   Leuk Lymphoma. 2025 Oct 6:1-11. doi: 10.1080/10428194.2025.2566317.
   PubMed     Abstract available
   
   
   September 2025
6. WANG Y, Xiao X, Zheng H, Bai J, et al
   The discussion on the differences in immune microenvironment between low-risk and high-risk myelodysplastic syndromes and acute myeloid leukemia.
   Leuk Lymphoma. 2025 Sep 9:1-16. doi: 10.1080/10428194.2025.2549519.
   PubMed     Abstract available
   
   
   
7. PARISI X, Ghosh A, Tang G, Jorgensen JL, et al
   Lineage switch of B-lymphoblastic leukemia with KMT2A::AFF1 fusion into acute myelomonocytic leukemia under blinatumomab therapy.
   Leuk Lymphoma. 2025 Sep 8:1-4. doi: 10.1080/10428194.2025.2549515.
   PubMed    
   
   
   
8. SINGH L, Rastogi K, Singh A, Sathapathy S, et al
   Methods for the analysis of leukemic infiltration within cerebrospinal fluid in acute lymphoblastic leukemia-a systematic review.
   Leuk Lymphoma. 2025 Sep 5:1-13. doi: 10.1080/10428194.2025.2550580.
   PubMed     Abstract available
   
   
   
9. XU K, Mellios Z, Hyun J, Childerhouse A, et al
   Diagnosis and management of acute erythroid leukemia (AEL).
   Leuk Lymphoma. 2025 Sep 2:1-5. doi: 10.1080/10428194.2025.2553166.
   PubMed    
   
   
   
10. BRAZEL D, Hermel DJ, Saven A
    Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia.
    Leuk Lymphoma. 2025 Sep 1:1-8. doi: 10.1080/10428194.2025.2548373.
    PubMed     Abstract available
    
    
    
11. ABBASI-SHAHKOUH A, Rashidan K, Azadmehr A, Atashi A, et al
    Exploring the role of neutrophil extracellular traps in leukemia: a comprehensive review.
    Leuk Lymphoma. 2025 Sep 1:1-11. doi: 10.1080/10428194.2025.2547990.
    PubMed     Abstract available
    
    
    August 2025
12. TESSIER S, Greipp PT, Jevremovic D, Alkhateeb HB, et al
    Acute leukemia of ambiguous lineage with KMT2A-alterations in adults.
    Leuk Lymphoma. 2025 Aug 25:1-6. doi: 10.1080/10428194.2025.2547988.
    PubMed    
    
    
    
13. LIPTON JH
    Indolent chronic myeloid leukemia - a historical dinosaur?
    Leuk Lymphoma. 2025 Aug 22:1-2. doi: 10.1080/10428194.2025.2536121.
    PubMed    
    
    
    
14. AMIRI D, Mirzaei M, Bahri T, Barkhordar M, et al
    Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen.
    Leuk Lymphoma. 2025 Aug 20:1-9. doi: 10.1080/10428194.2025.2548968.
    PubMed     Abstract available
    
    
    
15. KARRAR O, Kantarjian H, Haddad FG, Azevedo RS, et al
    Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase.
    Leuk Lymphoma. 2025 Aug 9:1-8. doi: 10.1080/10428194.2025.2542946.
    PubMed     Abstract available
    
    
    
16. MATSUI S, Nakahara W, Fukuda S, Hosoya M, et al
    Intrathecal methotrexate for meningeal acute lymphoblastic leukemia in a hemodialysis patient.
    Leuk Lymphoma. 2025 Aug 9:1-4. doi: 10.1080/10428194.2025.2544067.
    PubMed    
    
    
    
17. PARK H, Lee JH, Lee JH, Park HS, et al
    Effectiveness of prophylactic intrathecal chemotherapy and risk factors of central nervous system relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
    Leuk Lymphoma. 2025 Aug 7:1-11. doi: 10.1080/10428194.2025.2541302.
    PubMed     Abstract available
    
    
    
18. AGRAWAL V, Aldoss I, Pullarkat V
    Extramedullary sites of disease in B-cell acute lymphoblastic leukemia: incidence, biology, and treatment.
    Leuk Lymphoma. 2025 Aug 5:1-12. doi: 10.1080/10428194.2025.2541024.
    PubMed     Abstract available
    
    
    
19. ZIELONKA K, Izdebski B, Drozd-Sokolowska J, Pruszczyk-Matusiak K, et al
    Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group.
    Leuk Lymphoma. 2025 Aug 1:1-9. doi: 10.1080/10428194.2025.2535693.
    PubMed     Abstract available
    
    
    July 2025
20. LU L, Liang J, Wang L, Chen Z, et al
    Venetoclax promotes acute myeloid leukemia cells apoptosis by decreasing ac4C modification and mRNA expression of IMP3 through downregulating NAT10.
    Leuk Lymphoma. 2025 Jul 31:1-11. doi: 10.1080/10428194.2025.2540445.
    PubMed     Abstract available
    
    
    
21. PODGORICA M, Drivet E, Vestbostad J, Kvam AK, et al
    Azaindole 1, a selective Rock1/2 kinase inhibitor, induces G2/M arrest and cell death in B-cell acute lymphoblastic leukemia (B-ALL).
    Leuk Lymphoma. 2025 Jul 29:1-5. doi: 10.1080/10428194.2025.2536125.
    PubMed    
    
    
    
22. MULLIGAN SP, Thompson PA, Wight J, Anderson MA, et al
    Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.
    Leuk Lymphoma. 2025 Jul 27:1-11. doi: 10.1080/10428194.2025.2533498.
    PubMed     Abstract available
    
    
    
23. LIU YC, van Besien KW
    Chronic myelomonocytic leukemia (CMML): a genetically heterogeneous entity.
    Leuk Lymphoma. 2025 Jul 22:1-3. doi: 10.1080/10428194.2025.2527389.
    PubMed    
    
    
    
24. WU Y, Ke Q, Liu B, Luo W, et al
    KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications.
    Leuk Lymphoma. 2025 Jul 15:1-5. doi: 10.1080/10428194.2025.2532680.
    PubMed    
    
    
    
25. LI THS, Yuen CT, Hou HW, Lam CP, et al
    Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation.
    Leuk Lymphoma. 2025 Jul 14:1-3. doi: 10.1080/10428194.2025.2529451.
    PubMed    
    
    
    
26. ASHFAQ MO, Iqbal MS, Ashfaq L, Irfan U, et al
    Challenging diagnosis of chronic myelomonocytic leukemia (CMML) in a patient with Takayasu arteritis: case report.
    Leuk Lymphoma. 2025 Jul 13:1-4. doi: 10.1080/10428194.2025.2526792.
    PubMed    
    
    
    
27. KOFFMAN B, Warwick L, Haggert P, Patten PEM, et al
    A charter for improving care for people living with chronic lymphocytic leukemia: six principles for excellence.
    Leuk Lymphoma. 2025 Jul 12:1-7. doi: 10.1080/10428194.2025.2521656.
    PubMed     Abstract available
    
    
    
28. UYANIK MS, Jabbour E, Short N, Sasaki K, et al
    Nelarabine-related rhabdomyolysis in adult patients with T-cell lymphoblastic leukemia/lymphoma: a report of 6 patients.
    Leuk Lymphoma. 2025 Jul 6:1-3. doi: 10.1080/10428194.2025.2521649.
    PubMed    
    
    
    
29. FENG J, Qian W, Shan S, Wang G, et al
    Azathioprine as a substitute for 6-mercaptopurine in childhood acute lymphoblastic leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2025 Jul 6:1-9. doi: 10.1080/10428194.2025.2526795.
    PubMed     Abstract available
    
    
    
30. GULLAKSEN SE, Omsland M, Brevik M, Letzner J, et al
    CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors.
    Leuk Lymphoma. 2025;66:1211-1220.
    PubMed     Abstract available
    
    
    June 2025
31. SLATER VE, Carnahan RM, Strouse CS, O'Rorke MA, et al
    Changes in first-line treatment patterns according to frailty in chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2025 Jun 26:1-12. doi: 10.1080/10428194.2025.2522373.
    PubMed     Abstract available
    
    
    
32. SARANGARAJAN S, Meena JP, Gupta AK, Batra A, et al
    The prognostic implications of CDKN2A/2B deletion in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2025 Jun 25:1-14. doi: 10.1080/10428194.2025.2521658.
    PubMed     Abstract available
    
    
    
33. MAURO MJ, Hehlmann R, Williams LA, Goldberg SL, et al
    Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.
    Leuk Lymphoma. 2025 Jun 22:1-10. doi: 10.1080/10428194.2025.2495369.
    PubMed     Abstract available
    
    
    
34. SWAIN RN, Pattanaik S, Jain A, Wadhera S, et al
    Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax 400 mg despite lower pharmacokinetic exposure in newly diagnosed acute myeloid leukemia: less is enough.
    Leuk Lymphoma. 2025 Jun 22:1-5. doi: 10.1080/10428194.2025.2519921.
    PubMed    
    
    
    
35. KUNDU R, Soni K, Kundu R, Mukherjee S, et al
    State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA).
    Leuk Lymphoma. 2025 Jun 20:1-6. doi: 10.1080/10428194.2025.2515598.
    PubMed     Abstract available
    
    
    
36. PUROHIT BN, Mohan V, Capoor V, Jain S, et al
    Lower-dose venetoclax (LoVe) based regimes in children with acute leukemia.
    Leuk Lymphoma. 2025 Jun 18:1-4. doi: 10.1080/10428194.2025.2519920.
    PubMed    
    
    
    
37. LAI CE, Leahy TP, Turner AJ, Thomassen A, et al
    Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control
    Leuk Lymphoma. 2025 Jun 13:1-12. doi: 10.1080/10428194.2025.2514894.
    PubMed     Abstract available
    
    
    
38. SMITH CIE
    Resistance to BTK inhibitors in leukemia: cysteine 481 in BTK equals cysteine 515 in the BTK isomer BTK-C.
    Leuk Lymphoma. 2025 Jun 12:1-2. doi: 10.1080/10428194.2025.2518433.
    PubMed    
    
    
    
39. DAMPMANN M, von Tresckow B, Reinhardt HC, Kuppers R, et al
    Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor.
    Leuk Lymphoma. 2025 Jun 10:1-10. doi: 10.1080/10428194.2025.2513005.
    PubMed     Abstract available
    
    
    
40. KAMALLOO H, Fathi M, Bavandi S, Asadi F, et al
    Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jun 2:1-13. doi: 10.1080/10428194.2025.2507198.
    PubMed     Abstract available
    
    
    
41. JANY J, Mikesch JH, Wethmar K, Baden D, et al
    Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML).
    Leuk Lymphoma. 2025 Jun 2:1-12. doi: 10.1080/10428194.2025.2512029.
    PubMed     Abstract available
    
    
    May 2025
42. LEVY V, Srivastava T, Gautam R, Swami S, et al
    Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2025 May 23:1-9. doi: 10.1080/10428194.2025.2506501.
    PubMed     Abstract available
    
    
    
43. MEHTA P, Ngo D, Tinajero J, Agrawal V, et al
    Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults >/=40 years old.
    Leuk Lymphoma. 2025 May 21:1-5. doi: 10.1080/10428194.2025.2506003.
    PubMed    
    
    
    
44. SHI C, Li Y, Zou X, Yao D, et al
    AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor immune microenvironment in acute myeloid leukemia.
    Leuk Lymphoma. 2025 May 19:1-15. doi: 10.1080/10428194.2025.2504161.
    PubMed     Abstract available
    
    
    
45. HILL JW, Marvin-Peek J, Sasaki K, Bresser S, et al
    Central nervous system relapse of core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2025 May 19:1-4. doi: 10.1080/10428194.2025.2506505.
    PubMed    
    
    
    
46. TADMOR T, Lavie G, Melamed G, Alapi H, et al
    Intake of benzodiazepines in treatment naive chronic lymphocytic leukemia patients is associate with a shorter time to first treatment.
    Leuk Lymphoma. 2025 May 15:1-6. doi: 10.1080/10428194.2025.2504155.
    PubMed     Abstract available
    
    
    
47. OTHMAN T, Lo MM, Andreadis CB, Damon LE, et al
    Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2025 May 7:1-4. doi: 10.1080/10428194.2025.2496333.
    PubMed    
    
    
    
48. GORDON BK, Woyach JA
    The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics.
    Leuk Lymphoma. 2025;66:838-846.
    PubMed     Abstract available
    
    
    
49. MCKEAGUE S, Tam C
    Prognostic factors in chronic lymphocytic leukaemia - the old, the new and the future.
    Leuk Lymphoma. 2025;66:847-857.
    PubMed     Abstract available
    
    
    
50. RAMACHANDRA N, Vegivinti CTR, Sahu S, Sanawar R, et al
    Transforming growth factor beta receptor type I (TGF-betaRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS.
    Leuk Lymphoma. 2025;66:920-929.
    PubMed     Abstract available
    
    
    April 2025
51. SHALLIS RM, Weiss JJ, Winer ES, Badar T, et al
    Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
    Leuk Lymphoma. 2025 Apr 28:1-5. doi: 10.1080/10428194.2025.2496339.
    PubMed    
    
    
    
52. LAGANA A, Kasmi D, Diverio D, Bisegna ML, et al
    CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITD(mut)-AML): a flow-cytometric marker for an accurate diagnostic workup.
    Leuk Lymphoma. 2025 Apr 28:1-6. doi: 10.1080/10428194.2025.2497392.
    PubMed     Abstract available
    
    
    
53. ELHODAKY M, Duckett D, Santana-Santos L, Oh TS, et al
    Clinicopathological and global methylation profiling of acute myeloid leukemia with mutations in NPM1 and clonal hematopoiesis-related genes.
    Leuk Lymphoma. 2025 Apr 25:1-8. doi: 10.1080/10428194.2025.2495105.
    PubMed     Abstract available
    
    
    
54. BEHMAN J, Longobardi S, Kang G, Lingamurthy M, et al
    CD5- B-cell lymphocytic leukemia -a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus.
    Leuk Lymphoma. 2025 Apr 22:1-4. doi: 10.1080/10428194.2025.2492608.
    PubMed    
    
    
    
55. LEVANON E, Peles I, Meyer E, Tarab E, et al
    Prognostic impact of fever at presentation in acute myeloid leukemia: a retrospective cohort study.
    Leuk Lymphoma. 2025 Apr 17:1-11. doi: 10.1080/10428194.2025.2493342.
    PubMed     Abstract available
    
    
    
56. PATEL M, Zabor EC, Mohamed A, Zureigat H, et al
    Impact of TP53 mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary center.
    Leuk Lymphoma. 2025 Apr 9:1-6. doi: 10.1080/10428194.2025.2482131.
    PubMed     Abstract available
    
    
    
57. DHAKAL P, Armitage JO, Bhatt VR
    Academic and community cancer center collaboration in acute myeloid leukemia: a road map to optimize care delivery.
    Leuk Lymphoma. 2025 Apr 1:1-11. doi: 10.1080/10428194.2025.2484640.
    PubMed     Abstract available
    
    
    March 2025
58. KUGLER E, Dasdemir E, Bataller A, Wang B, et al
    Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions.
    Leuk Lymphoma. 2025 Mar 31:1-13. doi: 10.1080/10428194.2025.2477723.
    PubMed     Abstract available
    
    
    
59. JOHANSSON ALM S, Orrsjo G, Shah Barkhordar G, Rehammar A, et al
    Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation.
    Leuk Lymphoma. 2025 Mar 31:1-11. doi: 10.1080/10428194.2025.2482130.
    PubMed     Abstract available
    
    
    
60. FERREIRA JE, Wang CP, Aguayo-Hiraldo P, Raca G, et al
    Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy.
    Leuk Lymphoma. 2025 Mar 25:1-5. doi: 10.1080/10428194.2025.2482135.
    PubMed    
    
    
    
61. ROBAK T, Pluta A, Robak P, Janus A, et al
    Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies.
    Leuk Lymphoma. 2025 Mar 25:1-13. doi: 10.1080/10428194.2025.2475337.
    PubMed     Abstract available
    
    
    
62. JAIN N, Eyre TA, Winfree KB, Bhandari NR, et al
    Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2025 Mar 23:1-13. doi: 10.1080/10428194.2025.2482132.
    PubMed     Abstract available
    
    
    
63. MONSEES EL, Hauch RT, Wrzeszcz A, Spohn M, et al
    A case report of a pediatric T-cell acute lymphoblastic leukemia with a subclonal GCC2::PDGFRB t(2;5) translocation - implementation for the selection of MRD-targets.
    Leuk Lymphoma. 2025 Mar 19:1-5. doi: 10.1080/10428194.2025.2480395.
    PubMed    
    
    
    
64. AMREIN PC, Preffer FI, Fell G, Attar EC, et al
    Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.
    Leuk Lymphoma. 2025 Mar 12:1-11. doi: 10.1080/10428194.2025.2476655.
    PubMed     Abstract available
    
    
    
65. HOECHSTETTER MA, Wendtner CM
    Clinical trials in early-stage CLL: what has been learned and what's next?
    Leuk Lymphoma. 2025;66:378-388.
    PubMed     Abstract available
    
    
    
66. ALHAJAHJEH A, Patel KK, Shallis RM, Podoltsev NA, et al
    Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML.
    Leuk Lymphoma. 2025;66:488-496.
    PubMed     Abstract available
    
    
    
67. LI Q, Xing S, Zhang H, Mao X, et al
    FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement.
    Leuk Lymphoma. 2025;66:507-515.
    PubMed     Abstract available
    
    
    February 2025
68. TAN M, Lasica M, Donati V, Rady K, et al
    Avascular necrosis in older adolescents and adults with acute lymphoblastic leukemia treated with FRALLE protocols: a multicenter analysis of incidence, risk factors and morbidity.
    Leuk Lymphoma. 2025 Feb 27:1-7. doi: 10.1080/10428194.2025.2470784.
    PubMed     Abstract available
    
    
    
69. GRUESSNER C, Wiestner A, Sun C
    Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.
    Leuk Lymphoma. 2025 Feb 19:1-13. doi: 10.1080/10428194.2025.2466101.
    PubMed     Abstract available
    
    
    
70. SHESTAKOVA A, Haghighi N, Zhang Y, Tarabay J, et al
    Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) involving the central nervous system.
    Leuk Lymphoma. 2025 Feb 18:1-6. doi: 10.1080/10428194.2025.2452341.
    PubMed    
    
    
    
71. SUN Y, Liu N, Liu Y, Deng J, et al
    Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement.
    Leuk Lymphoma. 2025 Feb 10:1-4. doi: 10.1080/10428194.2025.2460046.
    PubMed    
    
    
    
72. THOMAS CJ, Porter D, Van Deerlin VM, Bhattacharyya S, et al
    Aleukemic soft-tissue relapse post allogeneic hematopoietic cell transplantation in T-prolymphocytic leukemia.
    Leuk Lymphoma. 2025 Feb 8:1-4. doi: 10.1080/10428194.2025.2462950.
    PubMed    
    
    
    
73. LANG F, Voss A, Kobbe G, Junghanss C, et al
    Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Feb 8:1-9. doi: 10.1080/10428194.2025.2460737.
    PubMed     Abstract available
    
    
    
74. CHIN KK, Derkach A, Famulare C, Gupta GK, et al
    HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.
    Leuk Lymphoma. 2025;66:270-278.
    PubMed     Abstract available
    
    
    January 2025
75. KRSTEVSKA BOZHINOVIKJ E, Matevska-Geshkovska N, Staninova Stojovska M, Gjorgievska E, et al
    Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 22:1-8. doi: 10.1080/10428194.2025.2456100.
    PubMed     Abstract available
    
    
    
76. JEONG Y
    Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutations and higher mutation burden in myeloproliferative CMML compared to myelodysplastic CMML.
    Leuk Lymphoma. 2025 Jan 17:1-10. doi: 10.1080/10428194.2025.2453093.
    PubMed     Abstract available
    
    
    
77. TESSIER S, McCullough KB, Gangat N, Begna KH, et al
    Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 16:1-5. doi: 10.1080/10428194.2024.2443017.
    PubMed    
    
    
    
78. HEILBRONNER AK, Blumberg O, Krez A, McMahon DJ, et al
    High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 15:1-4. doi: 10.1080/10428194.2025.2452340.
    PubMed    
    
    
    
79. ZHU H, Zhang C, Huang L, Zhang B, et al
    Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm.
    Leuk Lymphoma. 2025 Jan 15:1-12. doi: 10.1080/10428194.2025.2451064.
    PubMed     Abstract available
    
    
    
80. LI M, Zhao DQ, Kong XY, Wang SM, et al
    Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 11:1-11. doi: 10.1080/10428194.2025.2451059.
    PubMed     Abstract available
    
    
    
81. SENAPATI J, Kantarjian H, Habib D, Haddad FG, et al
    Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.
    Leuk Lymphoma. 2025 Jan 10:1-12. doi: 10.1080/10428194.2025.2449582.
    PubMed     Abstract available
    
    
    
82. ZHANG F, Liu Y, Zhu Y, Wang Q, et al
    Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia.
    Leuk Lymphoma. 2025 Jan 2:1-11. doi: 10.1080/10428194.2024.2441855.
    PubMed     Abstract available
    
    
    
83. YSEBAERT L, Mouchel PL, Laurent C, Quillet-Mary A, et al
    The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2025 Jan 2:1-13. doi: 10.1080/10428194.2024.2447362.
    PubMed     Abstract available
    
    
    December 2024
84. AVGERINOU G, Solomou EE, Filippidou M, Perganti F, et al
    Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia.
    Leuk Lymphoma. 2024 Dec 28:1-4. doi: 10.1080/10428194.2024.2445701.
    PubMed    
    
    
    
85. GUGLIELMANA V, Rossi D
    Prognostic and predictive impact of NOTCH1 mutation in chronic lymphocytic leukemia: a systematic review.
    Leuk Lymphoma. 2024 Dec 27:1-10. doi: 10.1080/10428194.2024.2441858.
    PubMed     Abstract available
    
    
    
86. NILSSON MS, Martner A, Wennstrom L, Hansson M, et al
    Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Dec 24:1-3. doi: 10.1080/10428194.2024.2444466.
    PubMed    
    
    
    
87. DAMPMANN M, Kibler A, von Tresckow J, Reinhardt HC, et al
    Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression pattern.
    Leuk Lymphoma. 2024 Dec 17:1-9. doi: 10.1080/10428194.2024.2438804.
    PubMed     Abstract available
    
    
    
88. OLIAI C, Park S, Damon LE, Jonas BA, et al
    CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
    Leuk Lymphoma. 2024 Dec 17:1-7. doi: 10.1080/10428194.2024.2438809.
    PubMed     Abstract available
    
    
    
89. SHELLEY CS, Galiegue-Zouitina S, Andritsos LA, Epperla N, et al
    The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease.
    Leuk Lymphoma. 2024 Dec 17:1-19. doi: 10.1080/10428194.2024.2438800.
    PubMed     Abstract available
    
    
    
90. ISHIKAWA C, Mori N
    ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of adult T-cell leukemia.
    Leuk Lymphoma. 2024 Dec 17:1-12. doi: 10.1080/10428194.2024.2441875.
    PubMed     Abstract available
    
    
    
91. KOVACH AE, Komova D, Itov A, Gaskova M, et al
    Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype.
    Leuk Lymphoma. 2024;65:1840-1852.
    PubMed     Abstract available
    
    
    
92. MINA A
    Targeted therapy in acute T-cell leukemia/lymphoma: are we close?
    Leuk Lymphoma. 2024 Dec 1:1-3. doi: 10.1080/10428194.2024.2432575.
    PubMed    
    
    
    
93. PAISIOU A, OIkonomopoulou C, Pavlidis D, Ampatzidou M, et al
    CDKN2A/B deletion as an independent negative prognostic factor for allogeneic hematopoietic stem cell transplantation in childhood B cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2434177.
    PubMed    
    
    
    
94. RIOS-OLAIS FA, Rodriguez-Rodriguez S, Mora-Canas A, Ramos-Penafiel CO, et al
    Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2432582.
    PubMed    
    
    
    
95. EHRMANN AS, Zadro A, Tausch E, Schneider C, et al
    The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL.
    Leuk Lymphoma. 2024;65:1941-1953.
    PubMed     Abstract available
    
    
    
96. ARAD-COHEN N, Messinger Y, Barzilai-Birenboim S, Ben-Harosh M, et al
    National study reveals gram negative bacteremia on contemporary pediatric AML protocol.
    Leuk Lymphoma. 2024;65:1991-1999.
    PubMed     Abstract available
    
    
    
97. TASHAKORI M, Yohe S, Linden MA, McKenna RW, et al
    The prognostic effect of blast count in TP53 mutant myeloid neoplasms -the Minnesota experience.
    Leuk Lymphoma. 2024;65:2151-2162.
    PubMed     Abstract available
    
    
    
98. BOHN JP, Stolzlechner V, Gobel G, Pirklbauer M, et al
    Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function.
    Leuk Lymphoma. 2024;65:2108-2115.
    PubMed     Abstract available
    
    
    November 2024
99. PAUL S, Jabbour E, Nichols ED, Short NJ, et al
    Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes.
    Leuk Lymphoma. 2024 Nov 29:1-11. doi: 10.1080/10428194.2024.2426052.
    PubMed     Abstract available
    
    
    
100. SHORT NJ, Wierzbowska A, Cluzeau T, Laribi K, et al
     Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia.
     Leuk Lymphoma. 2024 Nov 28:1-11. doi: 10.1080/10428194.2024.2431878.
     PubMed     Abstract available
     
     
     
101. MIMS A, Xie Z, Potluri R, Rotter D, et al
     Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia.
     Leuk Lymphoma. 2024 Nov 28:1-9. doi: 10.1080/10428194.2024.2425792.
     PubMed     Abstract available
     
     
     
102. COSTA A, Scalzulli E, Carmosino I, Ielo C, et al
     Clinical and biological advances of critical complications in acute myeloid leukemia.
     Leuk Lymphoma. 2024 Nov 24:1-20. doi: 10.1080/10428194.2024.2425051.
     PubMed     Abstract available
     
     
     
103. ARRIGO G, Scaldaferri M, Audisio E, Boscaro E, et al
     Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience.
     Leuk Lymphoma. 2024 Nov 8:1-2. doi: 10.1080/10428194.2024.2427266.
     PubMed    
     
     
     
104. KORSHOLM C, Bulow C, Christensen M, Dalhoff K, et al
     Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review.
     Leuk Lymphoma. 2024 Nov 7:1-11. doi: 10.1080/10428194.2024.2412289.
     PubMed     Abstract available
     
     
     
105. LECORNEC N, Duchmann M, Itzykson R
     Single-cell sequencing applications in acute myeloid leukemia.
     Leuk Lymphoma. 2024 Nov 4:1-15. doi: 10.1080/10428194.2024.2422833.
     PubMed     Abstract available
     
     
     
106. TAM C, Zhao FL, Azam S, Li SC, et al
     Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset.
     Leuk Lymphoma. 2024;65:1576-1585.
     PubMed     Abstract available
     
     
     October 2024
107. THARAKAN S, Tremblay D, Azzi J
     Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies.
     Leuk Lymphoma. 2024 Oct 25:1-14. doi: 10.1080/10428194.2024.2414112.
     PubMed     Abstract available
     
     
     
108. ROTTER LK, Alhajahjeh A, Stempel JM, Grimshaw AA, et al
     Analyzing determinants of premature trial discontinuation in leukemia clinical trials.
     Leuk Lymphoma. 2024 Oct 23:1-9. doi: 10.1080/10428194.2024.2416565.
     PubMed     Abstract available
     
     
     
109. KIM SA, Jung M, Kim H, Byun JM, et al
     MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study.
     Leuk Lymphoma. 2024 Oct 22:1-8. doi: 10.1080/10428194.2024.2414903.
     PubMed     Abstract available
     
     
     
110. DEHGHANI SS, Wang Y, Ramesh KH, Cooper D, et al
     Atypical chronic myeloid leukemia (CML) with ETV6-ABL1 mutation managed successfully with a third-generation TKI and hematopoietic stem cell transplant.
     Leuk Lymphoma. 2024 Oct 18:1-3. doi: 10.1080/10428194.2024.2403666.
     PubMed    
     
     
     
111. RIBERA JM, Torrent A
     Novel prognostic factors and therapeutic advances in adult acute lymphoblastic leukemia.
     Leuk Lymphoma. 2024 Oct 18:1-11. doi: 10.1080/10428194.2024.2416569.
     PubMed     Abstract available
     
     
     
112. KANKARIA RA, Jones JB, Zargari M, Alexander DW, et al
     Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax.
     Leuk Lymphoma. 2024 Oct 16:1-4. doi: 10.1080/10428194.2024.2416573.
     PubMed    
     
     
     
113. MOHAMMAD EM, El-Ayadi M, Kamel A, Ebeid E, et al
     Early impact of treatment modifications adopted for acute lymphoblastic leukemia during SARS-CoV-2 pandemic; a single center experience and lessons for LMICs.
     Leuk Lymphoma. 2024 Oct 9:1-7. doi: 10.1080/10428194.2024.2411432.
     PubMed     Abstract available
     
     
     
114. SHANG Q, Wang Y, Lu A, Jia Y, et al
     Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.
     Leuk Lymphoma. 2024 Oct 8:1-10. doi: 10.1080/10428194.2024.2406958.
     PubMed     Abstract available
     
     
     
115. BRUNER SA, DiPippo AJ, Rausch CR
     Dose-adjusted direct oral anticoagulants (DOACs) in patients with acute leukemia: experience of a tertiary cancer care center.
     Leuk Lymphoma. 2024 Oct 7:1-3. doi: 10.1080/10428194.2024.2411626.
     PubMed    
     
     
     
116. SHADMAN M, Salkar M, Srivastava B, Karve S, et al
     Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
     Leuk Lymphoma. 2024 Oct 1:1-10. doi: 10.1080/10428194.2024.2402814.
     PubMed     Abstract available
     
     
     September 2024
117. ZABLONSKI KG, Skupa SA, Eiken AP, Sundaram S, et al
     Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia.
     Leuk Lymphoma. 2024 Sep 27:1-9. doi: 10.1080/10428194.2024.2398663.
     PubMed     Abstract available
     
     
     
118. SHANGGUAN X, Huang Y, Chen C, Wu W, et al
     Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia.
     Leuk Lymphoma. 2024 Sep 23:1-12. doi: 10.1080/10428194.2024.2404957.
     PubMed     Abstract available
     
     
     
119. KOPMAR NE, Qu X, Liu Y, Gooley TA, et al
     Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia.
     Leuk Lymphoma. 2024 Sep 19:1-4. doi: 10.1080/10428194.2024.2404959.
     PubMed    
     
     
     
120. DE SA H, Deloughery T, Kaempf A, Lachowiez C, et al
     Thromboprophylaxis with intermediate dose enoxaparin during asparaginase containing induction for young adults with acute lymphoblastic leukemia.
     Leuk Lymphoma. 2024 Sep 18:1-10. doi: 10.1080/10428194.2024.2405874.
     PubMed     Abstract available
     
     
     
121. OMRAN MM, Ibrahim AB, Abdelfattah R, Moussa HS, et al
     The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib.
     Leuk Lymphoma. 2024 Sep 18:1-8. doi: 10.1080/10428194.2024.2403671.
     PubMed     Abstract available
     
     
     
122. CHEN EC, Flamand Y, Tiao E, DeAngelo DJ, et al
     Incidence, duration, and severity of neutropenia in adults with B-cell acute lymphoblastic leukemia receiving blinatumomab consolidation.
     Leuk Lymphoma. 2024 Sep 16:1-8. doi: 10.1080/10428194.2024.2402808.
     PubMed     Abstract available
     
     
     
123. YIN Z, Gao Y, Bu X, Wang J, et al
     Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis.
     Leuk Lymphoma. 2024 Sep 5:1-13. doi: 10.1080/10428194.2024.2400228.
     PubMed     Abstract available
     
     
     
124. HUNTER S, Ryland G, Pang JM, Ninkovic S, et al
     Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to TP53 dysfunction.
     Leuk Lymphoma. 2024 Sep 4:1-4. doi: 10.1080/10428194.2024.2398659.
     PubMed    
     
     
     
125. GIL KB, Abbott D, Amaya ML, Schwartz M, et al
     Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia.
     Leuk Lymphoma. 2024 Sep 4:1-3. doi: 10.1080/10428194.2024.2397570.
     PubMed    
     
     
     
126. DEODATO M, Frustaci AM, Zappaterra A, Rapella A, et al
     Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia.
     Leuk Lymphoma. 2024 Sep 2:1-12. doi: 10.1080/10428194.2024.2398660.
     PubMed     Abstract available
     
     
     
127. HAYASHI H, Morikawa Y, Akahoshi S, Ikegawa K, et al
     Octreotide as prophylaxis against asparaginase-associated pancreatitis: a case series study.
     Leuk Lymphoma. 2024;65:1366-1369.
     PubMed    
     
     
     
128. RAVANDI F, Subklewe M, Walter RB, Vachhani P, et al
     Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
     Leuk Lymphoma. 2024;65:1281-1291.
     PubMed     Abstract available
     
     
     
129. ABUASAB T, Mohamed S, Pemmaraju N, Kadia TM, et al
     BRAF mutation in myeloid neoplasm: incidences and clinical outcomes.
     Leuk Lymphoma. 2024;65:1344-1349.
     PubMed     Abstract available
     
     
     
130. SABILE JMG, Swords R, Tyner JW
     Evaluating targeted therapies in older patients with TP53-mutated AML.
     Leuk Lymphoma. 2024;65:1201-1218.
     PubMed     Abstract available
     
     
     
131. KOBAYASHI Y, Ando K, Imaizumi Y, Sakamoto H, et al
     RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma.
     Leuk Lymphoma. 2024 Sep 1:1-13. doi: 10.1080/10428194.2024.2393258.
     PubMed     Abstract available
     
     
     August 2024
132. SCHWARTZ MS, Muffly LS
     Predicting relapse in acute lymphoblastic leukemia.
     Leuk Lymphoma. 2024 Aug 31:1-7. doi: 10.1080/10428194.2024.2387728.
     PubMed     Abstract available
     
     
     
133. OSTERGAARD A, Boer JM, van Leeuwen FN, Pieters R, et al
     IKZF1 in acute lymphoblastic leukemia: the rise before the fall?
     Leuk Lymphoma. 2024 Aug 29:1-11. doi: 10.1080/10428194.2024.2396046.
     PubMed     Abstract available
     
     
     
134. NGO D, Tinajero J, Song JY, Ma H, et al
     The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia.
     Leuk Lymphoma. 2024 Aug 18:1-9. doi: 10.1080/10428194.2024.2392823.
     PubMed     Abstract available
     
     
     
135. PRASERTSAN P, McNeil EB, Songthawee N, Chavananon S, et al
     Risk factors and development of a predictive score model for tumor lysis syndrome in childhood leukemia: a 10-year experience from a single tertiary hospital in Thailand.
     Leuk Lymphoma. 2024 Aug 18:1-7. doi: 10.1080/10428194.2024.2390582.
     PubMed     Abstract available
     
     
     
136. JEANSELME P, Tavitian S, Lapierre L, Vergez F, et al
     Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.
     Leuk Lymphoma. 2024 Aug 14:1-6. doi: 10.1080/10428194.2024.2390572.
     PubMed     Abstract available
     
     
     
137. CELLINI A, Salvalaggio A, Velasco R, Arnan M, et al
     Arsenic trioxide-induced peripheral neuropathy: prospective clinical and neurophysiological evaluation in a cohort of patients with acute promyelocytic leukemia.
     Leuk Lymphoma. 2024 Aug 13:1-4. doi: 10.1080/10428194.2024.2391899.
     PubMed    
     
     
     
138. PELLAND AA, Deschenes-Simard X, Savard X, Giguere P, et al
     Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.
     Leuk Lymphoma. 2024 Aug 11:1-9. doi: 10.1080/10428194.2024.2390574.
     PubMed     Abstract available
     
     
     
139. HU D, Shen K, Guo Y, Bao XB, et al
     The clinical implications of BCOR mutations in a large cohort of acute myeloid leukemia patients: a 5-year single-center retrospective study.
     Leuk Lymphoma. 2024 Aug 10:1-10. doi: 10.1080/10428194.2024.2387730.
     PubMed     Abstract available
     
     
     
140. LIN L, Xue S, Chen J, Gu C, et al
     Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient.
     Leuk Lymphoma. 2024;65:1181-1185.
     PubMed    
     
     
     
141. VERVOORDELDONK MYL, Hengeveld PJ, Levin MD, Langerak AW, et al
     B cell receptor signaling proteins as biomarkers for progression of CLL requiring first-line therapy.
     Leuk Lymphoma. 2024;65:1031-1043.
     PubMed     Abstract available
     
     
     
142. MAEKAWA F, Hayashida M, Takeoka K, Fukutsuka K, et al
     Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively.
     Leuk Lymphoma. 2024;65:1100-1109.
     PubMed     Abstract available
     
     
     
143. CHARALAMPOUS C, Doucette K, Chappell A, Vesole DH, et al
     Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression.
     Leuk Lymphoma. 2024 Aug 1:1-4. doi: 10.1080/10428194.2024.2381647.
     PubMed    
     
     
     July 2024
144. DALAL P, Dalal J
     PTCy-ATG mutually exclusive or additive? Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
     Leuk Lymphoma. 2024 Jul 31:1-2. doi: 10.1080/10428194.2024.2379976.
     PubMed    
     
     
     
145. CHOI YJ, Kook HW, Lee ST, Song J, et al
     The utility of next generation sequencing-based minimal residual disease monitoring in a post-myeloproliferative neoplasm acute myeloid leukemia patient: a case report.
     Leuk Lymphoma. 2024 Jul 29:1-4. doi: 10.1080/10428194.2024.2385498.
     PubMed    
     
     
     
146. JAIN U, Rahim F, Jain B, Tresa Mathew A, et al
     Trends in location of death for individuals with acute myeloid leukemia in the United States.
     Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382330.
     PubMed    
     
     
     
147. ZHANG B, Mahsoub S, Weinberg O, Germans SK, et al
     Clinicopathologic characteristics of de novo NF1-mutated acute myeloid leukemia.
     Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382329.
     PubMed    
     
     
     
148. SRIPORNSAWAN P, Chavananon S, Kittivisuit S, Songthawee N, et al
     Long-term survival outcome of childhood acute myeloid leukemia: a 43-year experience in Thailand, a resource-limited country.
     Leuk Lymphoma. 2024 Jul 26:1-10. doi: 10.1080/10428194.2024.2382916.
     PubMed     Abstract available
     
     
     
149. TOHO M, Yasunaga M, Masuda Y, Shimura A, et al
     Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature.
     Leuk Lymphoma. 2024 Jul 25:1-5. doi: 10.1080/10428194.2024.2381646.
     PubMed    
     
     
     
150. FANG J, Shankar N, Bao L, Haag M, et al
     Near-tetraploidy/tetraploidy acute myeloid leukemia with clinical, pathologic and molecular characteristics.
     Leuk Lymphoma. 2024 Jul 25:1-10. doi: 10.1080/10428194.2024.2382923.
     PubMed     Abstract available
     
     
     
151. TARANTINI F, Cumbo C, Anelli L, Zagaria A, et al
     Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?
     Leuk Lymphoma. 2024 Jul 23:1-12. doi: 10.1080/10428194.2024.2381649.
     PubMed     Abstract available
     
     
     
152. MORENO-LORENZANA D, Juarez-Velazquez R, Reyes-Leon A, Martinez-Anaya D, et al
     CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia.
     Leuk Lymphoma. 2024 Jul 21:1-11. doi: 10.1080/10428194.2024.2378817.
     PubMed     Abstract available
     
     
     
153. TRAN QUANG V, Wagner-Ballon O, Sloma I
     Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia.
     Leuk Lymphoma. 2024 Jul 14:1-11. doi: 10.1080/10428194.2024.2378816.
     PubMed     Abstract available
     
     
     
154. BORSOI L, Costa F, Milano C, Segantin G, et al
     Elicitation of societal preferences for chronic lymphocytic leukemia's treatments: a discrete choice experiment.
     Leuk Lymphoma. 2024 Jul 9:1-11. doi: 10.1080/10428194.2024.2374041.
     PubMed     Abstract available
     
     
     
155. HU M, Li J, Hu T, Zhang Z, et al
     Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
     Leuk Lymphoma. 2024 Jul 7:1-10. doi: 10.1080/10428194.2024.2376179.
     PubMed     Abstract available
     
     
     
156. DIEBOLD K, Bourne G, Espinoza-Gutarra M, Al-Kadhimi Z, et al
     Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia.
     Leuk Lymphoma. 2024 Jul 7:1-3. doi: 10.1080/10428194.2024.2373324.
     PubMed    
     
     
     
157. TORELI ACM, Miranda-Galvis M, Sharara M, Addas-Carvalho M, et al
     Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States.
     Leuk Lymphoma. 2024 Jul 5:1-10. doi: 10.1080/10428194.2024.2367057.
     PubMed     Abstract available
     
     
     
158. LAVIE G, Tadmor T
     It's time to change the standard of care for hairy cell leukemia?!
     Leuk Lymphoma. 2024 Jul 5:1-3. doi: 10.1080/10428194.2024.2371497.
     PubMed    
     
     
     
159. ALHAJAHJEH A, Bewersdorf JP, Bystrom RP, Zeidan AM, et al
     Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome.
     Leuk Lymphoma. 2024 Jul 4:1-11. doi: 10.1080/10428194.2024.2367040.
     PubMed     Abstract available
     
     
     
160. TAKIZAWA J, Teshima T, Ennishi D, Ichikawa S, et al
     Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study.
     Leuk Lymphoma. 2024 Jul 1:1-9. doi: 10.1080/10428194.2024.2370436.
     PubMed     Abstract available
     
     
     
161. SURESH D, Rastogi P, Bal A, Lad D, et al
     Bridging the gap: understanding contemporary autopsies in acute leukemia by comparing ante-mortem and post-mortem profiles.
     Leuk Lymphoma. 2024 Jul 1:1-16. doi: 10.1080/10428194.2024.2372408.
     PubMed     Abstract available
     
     
     
162. GOERGEN E, Al-Sawaf O
     The prognostic significance of genomic complexity in patients with CLL.
     Leuk Lymphoma. 2024;65:873-881.
     PubMed     Abstract available
     
     
     June 2024
163. ANDERSON LJ, Girguis M, Kim E, Shewale J, et al
     A temporal and multinational assessment of acute myeloid leukemia (AML) cancer incidence, survival, and disease burden.
     Leuk Lymphoma. 2024 Jun 27:1-10. doi: 10.1080/10428194.2024.2360536.
     PubMed     Abstract available
     
     
     
164. YU G, Zhang W, Basyal M, Nishida Y, et al
     The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.
     Leuk Lymphoma. 2024 Jun 13:1-16. doi: 10.1080/10428194.2024.2364839.
     PubMed     Abstract available
     
     
     
165. ABE C, Keto J, Lilja M, Konradsen M, et al
     Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data.
     Leuk Lymphoma. 2024 Jun 11:1-9. doi: 10.1080/10428194.2024.2363430.
     PubMed     Abstract available
     
     
     
166. BHATLA T, Cooper S, Hogan LE
     Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what's next?
     Leuk Lymphoma. 2024 Jun 11:1-7. doi: 10.1080/10428194.2024.2362408.
     PubMed     Abstract available
     
     
     
167. CHANG JE, Wang T, Kim K, Folstad M, et al
     Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
     Leuk Lymphoma. 2024 Jun 10:1-9. doi: 10.1080/10428194.2024.2360535.
     PubMed     Abstract available
     
     
     
168. SHORT NJ, Kantarjian H, Jabbour E
     Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
     Leuk Lymphoma. 2024 Jun 8:1-13. doi: 10.1080/10428194.2024.2364043.
     PubMed     Abstract available
     
     
     
169. GERA K, Cline C, Al-Mansour Z, Medvec A, et al
     A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with resistant acute myeloid leukemia.
     Leuk Lymphoma. 2024 Jun 6:1-9. doi: 10.1080/10428194.2024.2361111.
     PubMed     Abstract available
     
     
     
170. SHOUSE G, Chen L, Siddiqi T, Muir A, et al
     A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
     Leuk Lymphoma. 2024 Jun 5:1-4. doi: 10.1080/10428194.2024.2361841.
     PubMed    
     
     
     
171. FREI CR, Ryan K, Obodozie-Ofoegbu GO, Moore AM, et al
     Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL).
     Leuk Lymphoma. 2024 Jun 4:1-4. doi: 10.1080/10428194.2024.2360526.
     PubMed    
     
     
     
172. FANG J, Bosma G, Aisner D, McMahon C, et al
     White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia.
     Leuk Lymphoma. 2024;65:800-807.
     PubMed     Abstract available
     
     
     May 2024
173. MINNEMA MC, Yin X, Davi R, Keeping S, et al
     Outcomes of patients aged >/=26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.
     Leuk Lymphoma. 2024 May 24:1-10. doi: 10.1080/10428194.2024.2353877.
     PubMed     Abstract available
     
     
     
174. BELDZINSKA-GADEK K, Zarzycka E, Pastuszak K, Borman K, et al
     Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia.
     Leuk Lymphoma. 2024 May 22:1-11. doi: 10.1080/10428194.2024.2351194.
     PubMed     Abstract available
     
     
     
175. ZHENG Y, Li J, Wen H, Weng K, et al
     Experience in improving treatment outcomes for childhood acute lymphoblastic leukemia: real-world results for a province in China, 2011-2020.
     Leuk Lymphoma. 2024 May 20:1-11. doi: 10.1080/10428194.2024.2350665.
     PubMed     Abstract available
     
     
     
176. MARVIN-PEEK J, Jen WY, Kantarjian HM, McCue D, et al
     Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
     Leuk Lymphoma. 2024 May 15:1-10. doi: 10.1080/10428194.2024.2349700.
     PubMed     Abstract available
     
     
     
177. DESPAS F, Chaouki M, de Barros S, Bonneau B, et al
     Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
     Leuk Lymphoma. 2024 May 15:1-3. doi: 10.1080/10428194.2024.2353330.
     PubMed    
     
     
     
178. WANG CP, Ferreira JE, Placek A, Aguayo-Hiraldo P, et al
     A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome.
     Leuk Lymphoma. 2024 May 11:1-5. doi: 10.1080/10428194.2024.2347577.
     PubMed     Abstract available
     
     
     
179. HUNTINGTON SF, Cheng WY, Sarpong EM, Leng S, et al
     Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
     Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631.
     PubMed     Abstract available
     
     
     
180. ROGERS KA, Thompson PA
     Pairing obinutuzumab with venetoclax in relapsed CLL.
     Leuk Lymphoma. 2024;65:543-545.
     PubMed    
     
     
     
181. GARCIAZ S, Berton G, Hospital MA, Guille A, et al
     Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.
     Leuk Lymphoma. 2024;65:700-703.
     PubMed    
     
     
     
182. OKABE S, Moriyama M, Gotoh A
     Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells.
     Leuk Lymphoma. 2024;65:696-699.
     PubMed    
     
     
     
183. FATIMA N, Shen Y, Crassini K, Burling O, et al
     The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.
     Leuk Lymphoma. 2024;65:585-597.
     PubMed     Abstract available
     
     
     April 2024
184. NESR G, Claudiani S, Milojkovic D, Innes A, et al
     Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia.
     Leuk Lymphoma. 2024 Apr 23:1-6. doi: 10.1080/10428194.2024.2343758.
     PubMed     Abstract available
     
     
     
185. STEMPEL JM, Shallis RM, Wong R, Podoltsev NA, et al
     Challenges in management of older patients with chronic myeloid leukemia.
     Leuk Lymphoma. 2024 Apr 23:1-14. doi: 10.1080/10428194.2024.2342559.
     PubMed     Abstract available
     
     
     
186. BEWERSDORF JP, Patel KK, Shallis RM, Podoltsev NA, et al
     Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.
     Leuk Lymphoma. 2024 Apr 22:1-9. doi: 10.1080/10428194.2024.2344052.
     PubMed     Abstract available
     
     
     
187. FLECK C, Karabinos A, Cook A, Moore DC, et al
     Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.
     Leuk Lymphoma. 2024 Apr 22:1-2. doi: 10.1080/10428194.2024.2341999.
     PubMed    
     
     
     
188. TINAJERO J, Ngo D, Zhang J, Tsai NC, et al
     High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
     Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506.
     PubMed    
     
     
     
189. STEIN EM, Fathi AT, Harb WA, Colak G, et al
     Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
     Leuk Lymphoma. 2024;65:503-510.
     PubMed     Abstract available
     
     
     
190. PARVIZ M, Agius R, Rotbain EC, Vainer N, et al
     Identifying CLL patients at high risk of atrial fibrillation on treatment using machine learning.
     Leuk Lymphoma. 2024;65:449-459.
     PubMed     Abstract available
     
     
     
191. ALDOSS I, Clark MC, Wang X, Forman SJ, et al
     Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL: are we there yet?
     Leuk Lymphoma. 2024;65:440-448.
     PubMed     Abstract available
     
     
     March 2024
192. CORTES J, Jonas BA, Schiller G, Mims A, et al
     Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
     Leuk Lymphoma. 2024 Mar 27:1-8. doi: 10.1080/10428194.2024.2333451.
     PubMed     Abstract available
     
     
     
193. MATTHEWS A, Fenu E, Skuli SJ, Harris JC, et al
     Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.
     Leuk Lymphoma. 2024 Mar 27:1-4. doi: 10.1080/10428194.2024.2332505.
     PubMed    
     
     
     
194. ABDALLAH AM, Hafez H, Madney Y, Ahmed S, et al
     Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.
     Leuk Lymphoma. 2024 Mar 21:1-4. doi: 10.1080/10428194.2024.2331625.
     PubMed    
     
     
     
195. LACZKO D, Poveda-Rogers C, Matthews AH, Snaith O, et al
     RAD21 mutations in acute myeloid leukemia.
     Leuk Lymphoma. 2024 Mar 20:1-7. doi: 10.1080/10428194.2024.2328233.
     PubMed     Abstract available
     
     
     
196. ZHU J, Xu M, Ru Y, Gong H, et al
     Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation.
     Leuk Lymphoma. 2024 Mar 12:1-9. doi: 10.1080/10428194.2024.2321322.
     PubMed     Abstract available
     
     
     February 2024
197. NASKAR S, Paul T, Kulkarni JD, Anand KC, et al
     TCF3::PBX1 fusion pediatric B acute lymphoblastic leukemia in disguise behind the eyes - an unusual clinicopathologic presentation with hyperdiploid clone.
     Leuk Lymphoma. 2024 Feb 26:1-5. doi: 10.1080/10428194.2024.2320827.
     PubMed    
     
     
     
198. HOFER KD, Buhler MM, Roncador M, Rechsteiner M, et al
     Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey.
     Leuk Lymphoma. 2024 Feb 22:1-8. doi: 10.1080/10428194.2024.2315171.
     PubMed     Abstract available
     
     
     
199. MURPHY L, Siegele B, Carstens B, Hartman L, et al
     A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy.
     Leuk Lymphoma. 2024 Feb 19:1-5. doi: 10.1080/10428194.2024.2315159.
     PubMed    
     
     
     
200. TANG K, Lipton JH
     Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
     Leuk Lymphoma. 2024 Feb 9:1-10. doi: 10.1080/10428194.2024.2313626.
     PubMed     Abstract available
     
     
     
201. YARED JA, Lee TY, Cooke CE, Johnson A, et al
     Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors.
     Leuk Lymphoma. 2024 Feb 7:1-11. doi: 10.1080/10428194.2024.2310150.
     PubMed     Abstract available
     
     
     
202. EL-ASHWAH S, Salmanton-Garcia J, Bilgin YM, Itri F, et al
     The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
     Leuk Lymphoma. 2024;65:199-208.
     PubMed     Abstract available
     
     
     
203. JOHNSON SM, Haberberger J, Galeotti J, Ramkissoon L, et al
     Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms.
     Leuk Lymphoma. 2024;65:209-218.
     PubMed     Abstract available
     
     
     January 2024
204. LEI MM, Sorial MN, Lou U, Yu M, et al
     Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
     Leuk Lymphoma. 2024 Jan 31:1-7. doi: 10.1080/10428194.2024.2310144.
     PubMed     Abstract available
     
     
     
205. NASR AA, Fund X, Barreau S, Desterke C, et al
     BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL).
     Leuk Lymphoma. 2024 Jan 31:1-4. doi: 10.1080/10428194.2024.2308665.
     PubMed    
     
     
     
206. TADMOR T, Levy Yurkovski I
     Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia.
     Leuk Lymphoma. 2024 Jan 22:1-4. doi: 10.1080/10428194.2024.2304026.
     PubMed    
     
     
     
207. FU S, Alhaj Z, Huynh D
     Prevalence of primary chronic lymphocytic leukemia in the United States: a cross-sectional study using the SEER database.
     Leuk Lymphoma. 2024 Jan 22:1-2. doi: 10.1080/10428194.2023.2300714.
     PubMed    
     
     
     
208. BANERJI V, Aw A, Laferriere N, Abdel-Samad N, et al
     Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
     Leuk Lymphoma. 2024 Jan 18:1-9. doi: 10.1080/10428194.2024.2301738.
     PubMed     Abstract available
     
     
     
209. NGO D, Tinajero J, Li S, Palmer J, et al
     Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
     Leuk Lymphoma. 2024 Jan 2:1-6. doi: 10.1080/10428194.2023.2292473.
     PubMed     Abstract available
     
     
     December 2023
210. SALTER B, Radford JM, Berg T, Leber B, et al
     The successful management of acute promyelocytic leukemia during pregnancy: a case report.
     Leuk Lymphoma. 2023 Dec 19:1-4. doi: 10.1080/10428194.2023.2295786.
     PubMed    
     
     
     
211. MUTTI M, Cordella S, Parisotto A, Bettelli F, et al
     Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature.
     Leuk Lymphoma. 2023 Dec 19:1-5. doi: 10.1080/10428194.2023.2294695.
     PubMed    
     
     
     
212. WANG L, Gao L, Liang Z, Cen X, et al
     Efficacy and safety of coadministration of venetoclax and anti-fungal agents under therapeutic drug monitor in unfit acute myeloid leukemia and high-risk myelodysplastic syndrome with neutropenia: a single-center retrospective study.
     Leuk Lymphoma. 2023 Dec 9:1-10. doi: 10.1080/10428194.2023.2290465.
     PubMed     Abstract available
     
     
     
213. JEN WY, Sasaki K, Rausch CR, DiNardo CD, et al
     Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
     Leuk Lymphoma. 2023 Dec 6:1-5. doi: 10.1080/10428194.2023.2290467.
     PubMed     Abstract available
     
     
     
214. ZHANG F, Hu GH, Zhang LP, Xu LP, et al
     Outcomes of haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in pediatric myeloid neoplasms post cytotoxic therapy: a case series study.
     Leuk Lymphoma. 2023 Dec 3:1-6. doi: 10.1080/10428194.2023.2281276.
     PubMed    
     
     
     
215. MURTON A, Forsyth C, Ross DM, Grigg A, et al
     Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.
     Leuk Lymphoma. 2023;64:2018-2025.
     PubMed     Abstract available
     
     
     
216. STEIN EM, de Botton S, Cluzeau T, Pigneux A, et al
     Use of tamibarotene, a potent and selective RARalpha agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
     Leuk Lymphoma. 2023;64:1992-2001.
     PubMed     Abstract available
     
     
     
217. REDD RA, Ford J, Lei M, Abramson JS, et al
     Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes.
     Leuk Lymphoma. 2023;64:2296-2305.
     PubMed     Abstract available
     
     
     
218. YANG T, Mahmood N, Goldberg B, Cevallos J, et al
     Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias.
     Leuk Lymphoma. 2023;64:2338-2342.
     PubMed    
     
     
     
219. TOMASULO E, Paul S, Mu R, Tian X, et al
     Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
     Leuk Lymphoma. 2023;64:2306-2315.
     PubMed     Abstract available
     
     
     
220. SMITH AL, Pal D, Martinez-Rico R, Eiken AP, et al
     Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
     Leuk Lymphoma. 2023;64:2333-2337.
     PubMed    
     
     
     
221. ZHANG X, Wang T, Zhang Y, Wang F, et al
     Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
     Leuk Lymphoma. 2023;64:2133-2139.
     PubMed     Abstract available
     
     
     November 2023
222. LAI X, Xiao J, Wang T, Hou C, et al
     Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission.
     Leuk Lymphoma. 2023 Nov 22:1-9. doi: 10.1080/10428194.2023.2284089.
     PubMed     Abstract available
     
     
     
223. OU J, Xu X, Deng S, Liang H, et al
     Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen.
     Leuk Lymphoma. 2023 Nov 8:1-9. doi: 10.1080/10428194.2023.2278026.
     PubMed     Abstract available
     
     
     
224. FATIMA N, Best OG, Belov L, Christopherson RI, et al
     The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells.
     Leuk Lymphoma. 2023 Nov 7:1-8. doi: 10.1080/10428194.2023.2275530.
     PubMed     Abstract available
     
     
     
225. KHOUDERCHAH CJ, Benitez LL, Marini BL, Fraga M, et al
     Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
     Leuk Lymphoma. 2023 Nov 6:1-7. doi: 10.1080/10428194.2023.2276056.
     PubMed     Abstract available
     
     
     
226. SASTOW D, Tatarian J, Salib C, Lin TL, et al
     Response to 'blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives'.
     Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2274658.
     PubMed    
     
     
     
227. FRATER JL
     Blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives.
     Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2273749.
     PubMed    
     
     
     
228. SOSNIA O, Pruszczyk K, Danecki M, Wasik-Szczepanek E, et al
     Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
     Leuk Lymphoma. 2023 Nov 3:1-12. doi: 10.1080/10428194.2023.2277140.
     PubMed     Abstract available
     
     
     
229. TRINQUAND A, Betts DR, Harte S, Sills A, et al
     Adapted risk stratification and intensive chemotherapy abrogate the poor prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21): a National cohort analysis.
     Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276061.
     PubMed    
     
     
     
230. RAMACHANDRA N, Gupta M, Schwartz L, Todorova T, et al
     Role of IL8 in myeloid malignancies.
     Leuk Lymphoma. 2023;64:1742-1751.
     PubMed     Abstract available
     
     
     
231. ITONAGA H, Kato T, Sawayama Y, Katsuoka S, et al
     RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL.
     Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276058.
     PubMed    
     
     
     October 2023
232. MERIC N, Albayrak E, Gulbas Z, Kocabas F, et al
     MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis.
     Leuk Lymphoma. 2023 Oct 30:1-12. doi: 10.1080/10428194.2023.2275532.
     PubMed     Abstract available
     
     
     
233. CONTRERAS YAMETTI GP, Robbins G, Chowdhury A, Narang S, et al
     SETD2 mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia.
     Leuk Lymphoma. 2023 Oct 24:1-13. doi: 10.1080/10428194.2023.2273752.
     PubMed     Abstract available
     
     
     
234. HUNTINGTON SF, de Nigris E, Puckett J, Kamal-Bahl S, et al
     Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
     Leuk Lymphoma. 2023 Oct 23:1-10. doi: 10.1080/10428194.2023.2256911.
     PubMed     Abstract available
     
     
     
235. LIAO C, Nie J, Xu XJ, Zhang JY, et al
     The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia.
     Leuk Lymphoma. 2023 Oct 11:1-9. doi: 10.1080/10428194.2023.2266075.
     PubMed     Abstract available
     
     
     
236. ZAHID MF, Kainthla R
     Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene.
     Leuk Lymphoma. 2023 Oct 9:1-5. doi: 10.1080/10428194.2023.2264428.
     PubMed    
     
     
     
237. GAUT D, Oliai C, Boiarsky J, Zhang S, et al
     Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
     Leuk Lymphoma. 2023 Oct 6:1-9. doi: 10.1080/10428194.2023.2264426.
     PubMed     Abstract available
     
     
     
238. YASU T, Gando Y, Shirota M, Kosugi N, et al
     Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.
     Leuk Lymphoma. 2023 Oct 5:1-4. doi: 10.1080/10428194.2023.2264427.
     PubMed    
     
     
     
239. SABILE JMG, Kaempf A, Tomic K, Manu GP, et al
     A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).
     Leuk Lymphoma. 2023;64:1689-1694.
     PubMed     Abstract available
     
     
     
240. CHAI J, Choudhuri J, Wang Q, Fang Y, et al
     Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
     Leuk Lymphoma. 2023;64:1662-1672.
     PubMed     Abstract available
     
     
     September 2023
241. LI L, Zhang R, Cao W, Bian Z, et al
     Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
     Leuk Lymphoma. 2023 Sep 21:1-10. doi: 10.1080/10428194.2023.2252948.
     PubMed     Abstract available
     
     
     
242. HUNTINGTON SF, Manzoor BS, Puckett JT, Kamal-Bahl S, et al
     Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
     Leuk Lymphoma. 2023 Sep 21:1-8. doi: 10.1080/10428194.2023.2255326.
     PubMed     Abstract available
     
     
     
243. LESEGRETAIN A, Brunner A, Benzohra A, Fathi AT, et al
     Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study.
     Leuk Lymphoma. 2023 Sep 15:1-9. doi: 10.1080/10428194.2023.2252123.
     PubMed     Abstract available
     
     
     
244. IELO C, Scalzulli E, Carmosino I, Pepe S, et al
     Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice.
     Leuk Lymphoma. 2023 Sep 10:1-3. doi: 10.1080/10428194.2023.2255804.
     PubMed     Abstract available
     
     
     
245. LA J, Lee MH, Brophy MT, Do NV, et al
     Baseline correlates of frailty and its association with survival in United States veterans with acute myeloid leukemia.
     Leuk Lymphoma. 2023 Sep 6:1-10. doi: 10.1080/10428194.2023.2254434.
     PubMed     Abstract available
     
     
     
246. BHATNAGAR B, Zhao Q, Mims AS, Vasu S, et al
     Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
     Leuk Lymphoma. 2023 Sep 4:1-10. doi: 10.1080/10428194.2023.2253480.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.